about
Stem-cell-based gene therapy for HIV infectionApproaches to preventative and therapeutic HIV vaccinesEvaluating the efficacy of therapeutic HIV vaccines through analytical treatment interruptionsResistance mutations and CTL epitopes in archived HIV-1 DNA of patients on antiviral treatment: toward a new concept of vaccineWillingness to participate in HIV therapeutic vaccine trials among HIV-infected patients on ART in ChinaLatency reversal and viral clearance to cure HIV-1.Prospects for treatment of latent HIV.Generation and characterization of a defective HIV-1 Virus as an immunogen for a therapeutic vaccine.Use of an Sm-p80-based therapeutic vaccine to kill established adult schistosome parasites in chronically infected baboons.Challenges in HIV Vaccine Research for Treatment and Prevention.Intranasal administration of a therapeutic HIV vaccine (Vacc-4x) induces dose-dependent systemic and mucosal immune responses in a randomized controlled trialRelationship of HIV reservoir characteristics with immune status and viral rebound kinetics in an HIV therapeutic vaccine study.Exploring the potential of monoclonal antibody therapeutics for HIV-1 eradication.Eradicating HIV-1 infection: seeking to clear a persistent pathogen.HIV-1 Tat immunization restores immune homeostasis and attacks the HAART-resistant blood HIV DNA: results of a randomized phase II exploratory clinical trialImmunotherapy with an HIV-DNA Vaccine in Children and Adults.HIV-1 Reservoir Dynamics after Vaccination and Antiretroviral Therapy Interruption Are Associated with Dendritic Cell Vaccine-Induced T Cell Responses.Therapeutic Vaccination With Dendritic Cells Loaded With Autologous HIV Type 1-Infected Apoptotic Cells.Effective Cytotoxic T Lymphocyte Targeting of Persistent HIV-1 during Antiretroviral Therapy Requires Priming of Naive CD8+ T CellsHIV-Tat immunization induces cross-clade neutralizing antibodies and CD4(+) T cell increases in antiretroviral-treated South African volunteers: a randomized phase II clinical trialTranslation of biomedical prevention strategies for HIV: prospects and pitfalls.Dendritic cell based vaccines for HIV infection: the way ahead.HIV-1 latency: an update of molecular mechanisms and therapeutic strategies.Safety and immunogenicity of a modified vaccinia Ankara-based HIV-1 vaccine (MVA-B) in HIV-1-infected patients alone or in combination with a drug to reactivate latent HIV-1.Personalized gene therapy locks out HIV, paving the way to control virus without antiretroviral drugs.Can HIV-1-Specific ADCC Assist the Clearance of Reactivated Latently Infected Cells?Development of a novel AIDS vaccine: the HIV-1 transactivator of transcription protein vaccine.Immunotherapeutic Approaches for the Control and Eradication of HIV.New challenges in therapeutic vaccines against HIV infection.Programming T cell Killers for an HIV Cure: Teach the New Dogs New Tricks and Let the Sleeping Dogs LieScreening of an FDA-approved compound library identifies levosimendan as a novel anti-HIV-1 agent that inhibits viral transcription.Monocytes Phenotype and Cytokine Production in Human Immunodeficiency Virus-1 Infected Patients Receiving a Modified Vaccinia Ankara-Based HIV-1 Vaccine: Relationship to CD300 Molecules Expression.Genome-wide scan in two groups of HIV-infected patients treated with dendritic cell-based immunotherapy.A Phase I Randomized Therapeutic MVA-B Vaccination Improves the Magnitude and Quality of the T Cell Immune Responses in HIV-1-Infected Subjects on HAART.Immune Interventions to Eliminate the HIV Reservoir.
P2860
Q24607667-674E0530-3464-42BF-806B-E7D2B14E8F02Q26764851-7D7BA9B8-CE83-4286-97B4-1A8E35847060Q26777442-5A41F510-B4AD-49C8-BFC4-CCD966EF916AQ28534573-3591709C-5A84-437E-88A4-EE38DC70697BQ28544731-591B42FF-DFA0-4616-A05D-0B7CDF9C4A64Q30248766-018812C2-404C-4ED9-9967-7CF2B28201E4Q30424413-9EC7E9E4-3F89-4884-A39E-DA73FF7C80F5Q31106756-92A0BA87-B788-4D38-ABFF-B337D3C21BE4Q33684408-386ABF72-2B2D-47DF-9D75-80012B319904Q34148683-E6DD558A-4659-4CCA-944C-701AD8AC65FFQ34513477-1C54EE30-ED45-4F4D-8078-3982D2E55C4DQ34713877-3ECC2BD5-DAEE-4B35-BE56-F97D5D45D1A2Q34869927-6AB86343-2C2C-4C80-9786-33D298B1B8CFQ35252186-1622E728-99B7-44F2-914F-E8FD1D1F06ECQ35552889-82EB9CE2-4E1E-4D37-AD3D-1E6F7A8C69CAQ35826642-F37FCAF6-9DB2-454F-8D83-55B1B88B31FFQ35973632-E7F2CA07-A304-4A12-BC46-D52C0AF387D9Q36745227-60765947-521C-480B-B3F9-C57655830F7FQ36974205-23C9BCDD-E353-48B8-AD8A-85664F7FCDB8Q36986644-4D15B87F-963D-4CD8-A296-B63A0AFCA142Q37051717-AEE1B03C-E183-44FA-B3D2-59F3EB77CECAQ38126373-9EBADC71-9D7A-4887-B17A-E160521FCEA5Q38204866-05C84F89-F5EC-4F68-A9DC-BDC8EBB99518Q38415577-0DEDD875-688D-43F1-81A1-B17E5ED928AEQ38462651-F436442B-3254-4110-99CC-BDD6DC802145Q38527822-21A5D5B0-2C80-46F1-8961-97B7D1B49611Q38533881-A13E6653-6D94-4364-9140-8465E5A785DDQ38635401-73DE4EC2-2CFF-429C-9175-1FF6947BFC32Q38692205-3E466451-24B6-4012-A1F4-9140CAEA7AADQ39201703-00D0CA84-74C8-4FBB-95DC-027A0CC66E13Q40070005-6A9F35D4-673B-48A0-9922-5D384B2284C7Q40091488-3652065D-0EFF-4331-A900-C0CCE881178CQ40516382-0909014A-44BC-424C-AA72-32A811E1EEDDQ40919787-DFF290E3-83B8-4F52-8E16-F00DD55029D4Q47600062-6FE12EED-A3BF-4F6F-A1D8-BE06D3EC28E3
P2860
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh-hant
name
Therapeutic vaccines against HIV infection.
@en
type
label
Therapeutic vaccines against HIV infection.
@en
prefLabel
Therapeutic vaccines against HIV infection.
@en
P2093
P2860
P356
P1476
Therapeutic vaccines against HIV infection.
@en
P2093
Josep M Gatell
Montserrat Plana
Teresa Gallart
P2860
P304
P356
10.4161/HV.19555
P577
2012-05-01T00:00:00Z